Etoricoxib and Naproxen May Have Long-Term Efficacy and Tolerability for OA Treatment CME

News Maker: Laurie Barclay, MD CME Communicator: Laurie Barclay, MD Disclosures Accomplishment Date: August 6, 2007 ; Valid for accomplishment through August 6, 2008 Credits Available Physicians - boundary of 0.25 AMA PRA Conception 1 Credit(s) â„¢ for physicians; Mob Physicians - up to 0.25 AAFP Prescribed credit(s) for physicians.
August 6, 2007 — Arcoxia (60 mg once daily) has similar efficacy as naproxen (500 mg twice daily) in controlling osteoarthritis (OA) and both are well tolerated, according to a combined analytic thinking of 2 long-term randomized controlled trials published in the July content of Chronological record of the Rheumatic Diseases .
“Etoricoxib is a COX [cyclo-oxygenase]-2 selective inhibitor that has demonstrated efficacy in patients with OA,” write J.Y.
Reginster, MD, PhD, from the Polycliniques Universitaires L.
Brull in Urban center, Belgium, and colleagues. “Recent studies have suggested that COX-2 selective inhibitors are associated with an increased risk of thrombotic cardiovascular (CV) events in relation with vesper.
Data are also available that suggest that traditional NSAIDs [nonsteroidal anti-inflammatory drugs] are associated with increased CV risk.”
At 80 clinical centers in 19 countries, 997 patients with hip or knee OA entered 2 double-blind, parallel-group trials, each with a 12-week part 1, a 40-week part 2, and an 86-week pedagogy.
Patients randomized to receive medicine during part 1 received etoricoxib or naproxen (1:1 ratio) during part 2 and the longness, whereas patients randomized to receive etoricoxib or naproxen during part 1 continued to receive the same intervention throughout part 2 and the extension service.
This is a part of article Etoricoxib and Naproxen May Have Long-Term Efficacy and Tolerability for OA Treatment CME Taken from "Generic Arcoxia (Etoricoxib)" Information Blog